Psyence Biomedical PBM Income Statement (2022-2026)

NASDAQ PBM
$4.84 +0.10 (+2.11%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Psyence Biomedical Quarterly Income Statement

Periods 8 quarters
Latest Mar 2026

Psyence Biomedical income statement data for the quarter ended Mar 2026. This income statement covers 8 quarters of results from Sep 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2022 Mar2023 Sep2023 Mar2024 Sep2024 Mar2025 Sep2025 Mar2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 0.31M0.55M
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot) 0.00M-0.00M
Research & DevelopmentR&D -0.01M0.27M0.36M
Wages, Salaries and OtherWages 1.22M0.20M0.37M0.88M
Selling, General & AdministrativeSG&A 0.78M1.84M0.24M0.22M
Operating ExpensesOpex 0.78M1.84M0.51M0.57M
EBIT -3.16M-0.20M1.16M-1.51M
Non-operating items
Non Operating Interest Expenses -0.03M0.00M-0.00M
Interest & Investment IncomeInt & Inv Inc 0.92M0.84M0.07M
Other Non Operating IncomeOther Non Op Inc. 5.63M0.03M0.26M-0.10M636.00
Non Operating IncomeNon Op. Inc. 6.55M1.11M
Net income details
EBT -3.23M-0.18M1.16M-1.50M
Profit After TaxPAT 5.76M-3.21M0.74M0.14M-0.75M
Equity Income -0.05M
Income from Continuing OperationsIncome (Continuing) -3.16M-0.18M1.16M-1.50M
Consolidated Net IncomeConsol Net Inc. -3.16M-0.18M1.16M-1.50M
Income towards Parent CompanyParent Net Inc -3.16M-0.18M1.16M-1.50M
Net Income towards Common StockholdersNet Income -3.16M-0.18M1.16M-1.50M
Additional items
EPS (Basic) -0.573.73-4.85
Shares Outstanding 0.31M0.31M0.31M0.31M0.31M0.55M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 0.55M
EBITDA -3.16M-0.20M1.16M-1.51M
Interest ExpensesInt Expense 0.03M0.00M-0.00M